| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vitrectomy | 15 | 2021 | 26 | 5.710 |
Why?
|
| Macular Edema | 10 | 2016 | 24 | 4.230 |
Why?
|
| Angiogenesis Inhibitors | 10 | 2022 | 77 | 3.600 |
Why?
|
| Tomography, Optical Coherence | 24 | 2021 | 223 | 3.380 |
Why?
|
| Diabetic Retinopathy | 11 | 2018 | 53 | 3.060 |
Why?
|
| Retinal Detachment | 5 | 2022 | 18 | 2.550 |
Why?
|
| Retinal Diseases | 6 | 2019 | 33 | 2.430 |
Why?
|
| Dexamethasone | 6 | 2017 | 205 | 2.340 |
Why?
|
| Visual Acuity | 16 | 2021 | 126 | 2.240 |
Why?
|
| Vitreous Body | 8 | 2022 | 31 | 2.200 |
Why?
|
| Bevacizumab | 7 | 2016 | 59 | 2.130 |
Why?
|
| Glucocorticoids | 7 | 2016 | 188 | 2.060 |
Why?
|
| Intravitreal Injections | 12 | 2022 | 49 | 1.980 |
Why?
|
| Wet Macular Degeneration | 4 | 2016 | 26 | 1.880 |
Why?
|
| Macula Lutea | 4 | 2017 | 22 | 1.580 |
Why?
|
| Retinal Perforations | 3 | 2022 | 8 | 1.460 |
Why?
|
| Laser Coagulation | 3 | 2016 | 15 | 1.460 |
Why?
|
| Eye Injuries, Penetrating | 3 | 2021 | 6 | 1.440 |
Why?
|
| Eye Foreign Bodies | 3 | 2021 | 9 | 1.430 |
Why?
|
| Triamcinolone Acetonide | 4 | 2015 | 14 | 1.380 |
Why?
|
| Sclerostomy | 4 | 2017 | 4 | 1.230 |
Why?
|
| Retinal Pigment Epithelium | 4 | 2017 | 35 | 1.230 |
Why?
|
| Retinal Vein Occlusion | 4 | 2016 | 18 | 1.180 |
Why?
|
| Endotamponade | 4 | 2016 | 7 | 1.180 |
Why?
|
| Choroidal Neovascularization | 3 | 2016 | 28 | 1.140 |
Why?
|
| Macular Degeneration | 6 | 2016 | 187 | 1.130 |
Why?
|
| Retina | 8 | 2021 | 124 | 1.110 |
Why?
|
| Sclera | 3 | 2017 | 10 | 1.110 |
Why?
|
| Vitreous Detachment | 2 | 2017 | 2 | 1.090 |
Why?
|
| Tissue Adhesions | 2 | 2017 | 20 | 1.080 |
Why?
|
| Fluorescein Angiography | 9 | 2018 | 58 | 1.030 |
Why?
|
| Aging | 3 | 2017 | 744 | 1.010 |
Why?
|
| Fovea Centralis | 4 | 2018 | 17 | 1.000 |
Why?
|
| Eye Infections, Bacterial | 2 | 2016 | 6 | 0.980 |
Why?
|
| Lens Implantation, Intraocular | 3 | 2016 | 9 | 0.970 |
Why?
|
| Silicone Oils | 2 | 2016 | 2 | 0.950 |
Why?
|
| Ophthalmology | 2 | 2015 | 24 | 0.930 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2016 | 55 | 0.900 |
Why?
|
| Lens, Crystalline | 2 | 2016 | 17 | 0.890 |
Why?
|
| Aged, 80 and over | 16 | 2017 | 5422 | 0.850 |
Why?
|
| Humans | 54 | 2022 | 62955 | 0.850 |
Why?
|
| Aged | 24 | 2018 | 14296 | 0.800 |
Why?
|
| Male | 30 | 2021 | 29602 | 0.770 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 1593 | 0.750 |
Why?
|
| Cataract Extraction | 3 | 2016 | 37 | 0.750 |
Why?
|
| Suture Techniques | 3 | 2017 | 99 | 0.730 |
Why?
|
| Cataract | 3 | 2016 | 54 | 0.720 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2021 | 9 | 0.710 |
Why?
|
| Vascular Endothelial Growth Factor A | 6 | 2016 | 206 | 0.710 |
Why?
|
| Postoperative Complications | 4 | 2016 | 1292 | 0.680 |
Why?
|
| Female | 29 | 2018 | 32610 | 0.660 |
Why?
|
| Middle Aged | 23 | 2018 | 17422 | 0.660 |
Why?
|
| Pentosan Sulfuric Polyester | 1 | 2019 | 1 | 0.660 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2019 | 14 | 0.650 |
Why?
|
| Sutures | 2 | 2016 | 41 | 0.630 |
Why?
|
| Multimodal Imaging | 1 | 2019 | 67 | 0.620 |
Why?
|
| Models, Biological | 4 | 2018 | 1181 | 0.610 |
Why?
|
| Vitreoretinal Surgery | 1 | 2018 | 4 | 0.600 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2016 | 122 | 0.590 |
Why?
|
| Eye Burns | 1 | 2017 | 2 | 0.570 |
Why?
|
| Video Recording | 1 | 2018 | 133 | 0.570 |
Why?
|
| Virus Activation | 1 | 2017 | 24 | 0.570 |
Why?
|
| Keratitis, Herpetic | 1 | 2017 | 10 | 0.560 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2015 | 233 | 0.560 |
Why?
|
| Sunlight | 1 | 2017 | 30 | 0.560 |
Why?
|
| Herpes Simplex | 1 | 2017 | 50 | 0.550 |
Why?
|
| Teaching | 1 | 2018 | 156 | 0.550 |
Why?
|
| Diathermy | 1 | 2017 | 2 | 0.540 |
Why?
|
| Radiation Injuries | 1 | 2017 | 65 | 0.540 |
Why?
|
| Retinal Hemorrhage | 1 | 2016 | 7 | 0.530 |
Why?
|
| Panuveitis | 1 | 2016 | 1 | 0.530 |
Why?
|
| Lens Capsule, Crystalline | 1 | 2016 | 3 | 0.530 |
Why?
|
| Ultraviolet Rays | 1 | 2017 | 136 | 0.520 |
Why?
|
| Eye Infections, Fungal | 1 | 2016 | 2 | 0.520 |
Why?
|
| Education, Medical | 1 | 2018 | 182 | 0.510 |
Why?
|
| Histoplasmosis | 1 | 2016 | 24 | 0.510 |
Why?
|
| Vitreous Hemorrhage | 1 | 2016 | 3 | 0.500 |
Why?
|
| Point Mutation | 1 | 2016 | 166 | 0.500 |
Why?
|
| Choroid | 1 | 2016 | 26 | 0.500 |
Why?
|
| Endophthalmitis | 1 | 2016 | 12 | 0.500 |
Why?
|
| Drug Implants | 4 | 2017 | 15 | 0.500 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2017 | 173 | 0.500 |
Why?
|
| Calcinosis | 1 | 2016 | 83 | 0.490 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2016 | 126 | 0.490 |
Why?
|
| Environmental Exposure | 1 | 2017 | 220 | 0.490 |
Why?
|
| Prospective Studies | 7 | 2018 | 3266 | 0.490 |
Why?
|
| Histiocytosis, Sinus | 1 | 2015 | 2 | 0.480 |
Why?
|
| Choroid Diseases | 1 | 2015 | 5 | 0.480 |
Why?
|
| Glycoproteins | 1 | 2016 | 187 | 0.480 |
Why?
|
| Fibrinolytic Agents | 1 | 2016 | 169 | 0.480 |
Why?
|
| Choroid Neoplasms | 1 | 2015 | 21 | 0.470 |
Why?
|
| Granuloma | 1 | 2015 | 41 | 0.470 |
Why?
|
| Syphilis | 1 | 2015 | 25 | 0.460 |
Why?
|
| Retrospective Studies | 10 | 2016 | 6564 | 0.460 |
Why?
|
| Retinal Necrosis Syndrome, Acute | 1 | 2014 | 1 | 0.460 |
Why?
|
| Eye Infections, Viral | 1 | 2014 | 3 | 0.450 |
Why?
|
| Electrocoagulation | 1 | 2014 | 12 | 0.450 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 144 | 0.450 |
Why?
|
| Medical Record Linkage | 1 | 2014 | 21 | 0.450 |
Why?
|
| Lens Subluxation | 2 | 2016 | 2 | 0.450 |
Why?
|
| Staphylococcal Infections | 1 | 2016 | 130 | 0.450 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2014 | 16 | 0.450 |
Why?
|
| Geographic Atrophy | 1 | 2014 | 20 | 0.440 |
Why?
|
| Catheterization | 1 | 2013 | 111 | 0.410 |
Why?
|
| Uveitis, Intermediate | 1 | 2013 | 1 | 0.410 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2014 | 103 | 0.410 |
Why?
|
| RNA-Binding Proteins | 1 | 2016 | 434 | 0.400 |
Why?
|
| Foreign-Body Migration | 1 | 2013 | 21 | 0.400 |
Why?
|
| Drainage | 1 | 2013 | 154 | 0.400 |
Why?
|
| Scotoma | 1 | 2012 | 6 | 0.400 |
Why?
|
| Herpesvirus 4, Human | 1 | 2014 | 196 | 0.400 |
Why?
|
| Cognition Disorders | 1 | 2014 | 220 | 0.390 |
Why?
|
| Ketorolac Tromethamine | 1 | 2012 | 5 | 0.390 |
Why?
|
| Eye Pain | 1 | 2012 | 4 | 0.390 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 447 | 0.390 |
Why?
|
| Neuropsychological Tests | 1 | 2014 | 390 | 0.380 |
Why?
|
| Diabetes Mellitus | 1 | 2017 | 536 | 0.380 |
Why?
|
| Scleral Buckling | 1 | 2011 | 1 | 0.370 |
Why?
|
| Cryosurgery | 1 | 2011 | 27 | 0.370 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 2148 | 0.370 |
Why?
|
| Melanoma | 1 | 2015 | 332 | 0.360 |
Why?
|
| Dementia | 1 | 2014 | 258 | 0.350 |
Why?
|
| Multiple Myeloma | 1 | 2016 | 348 | 0.350 |
Why?
|
| Young Adult | 6 | 2021 | 4658 | 0.350 |
Why?
|
| Follow-Up Studies | 5 | 2016 | 2449 | 0.350 |
Why?
|
| Adult | 13 | 2018 | 16688 | 0.340 |
Why?
|
| Membrane Proteins | 1 | 2016 | 894 | 0.340 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 208 | 0.340 |
Why?
|
| Choroiditis | 1 | 2009 | 1 | 0.330 |
Why?
|
| Retinal Vessels | 3 | 2018 | 18 | 0.330 |
Why?
|
| Phacoemulsification | 1 | 2009 | 9 | 0.320 |
Why?
|
| Pain | 1 | 2012 | 407 | 0.310 |
Why?
|
| Tachyphylaxis | 1 | 2008 | 3 | 0.310 |
Why?
|
| Intraoperative Complications | 1 | 2009 | 90 | 0.300 |
Why?
|
| Case-Control Studies | 3 | 2017 | 1116 | 0.270 |
Why?
|
| Alzheimer Disease | 1 | 2014 | 718 | 0.270 |
Why?
|
| Semaphorins | 2 | 2016 | 4 | 0.270 |
Why?
|
| Hospitalization | 1 | 2014 | 1347 | 0.270 |
Why?
|
| Swine | 2 | 2018 | 370 | 0.240 |
Why?
|
| Microsurgery | 2 | 2016 | 51 | 0.230 |
Why?
|
| Sulfur Hexafluoride | 2 | 2016 | 3 | 0.230 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2018 | 667 | 0.220 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 870 | 0.220 |
Why?
|
| Fluorocarbons | 2 | 2016 | 38 | 0.220 |
Why?
|
| Adolescent | 4 | 2017 | 6202 | 0.210 |
Why?
|
| Exudates and Transudates | 2 | 2016 | 11 | 0.210 |
Why?
|
| Analysis of Variance | 2 | 2017 | 608 | 0.210 |
Why?
|
| Incidence | 2 | 2017 | 1373 | 0.210 |
Why?
|
| Indocyanine Green | 2 | 2015 | 10 | 0.200 |
Why?
|
| Treatment Outcome | 4 | 2016 | 5608 | 0.200 |
Why?
|
| Coloring Agents | 2 | 2015 | 54 | 0.190 |
Why?
|
| Intraocular Pressure | 2 | 2013 | 73 | 0.180 |
Why?
|
| Child | 3 | 2016 | 4484 | 0.180 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2018 | 44 | 0.180 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 464 | 0.180 |
Why?
|
| Pain Measurement | 2 | 2012 | 343 | 0.170 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 1545 | 0.170 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 2181 | 0.170 |
Why?
|
| Cystitis, Interstitial | 1 | 2019 | 5 | 0.160 |
Why?
|
| Early Diagnosis | 3 | 2018 | 97 | 0.160 |
Why?
|
| Computer Simulation | 1 | 2022 | 478 | 0.160 |
Why?
|
| Area Under Curve | 2 | 2018 | 146 | 0.160 |
Why?
|
| Angiography | 1 | 2018 | 151 | 0.140 |
Why?
|
| Automation | 1 | 2018 | 54 | 0.140 |
Why?
|
| Bruch Membrane | 2 | 2015 | 9 | 0.140 |
Why?
|
| Germany | 1 | 2017 | 53 | 0.140 |
Why?
|
| Intraoperative Period | 1 | 2017 | 34 | 0.140 |
Why?
|
| Furin | 1 | 2016 | 11 | 0.130 |
Why?
|
| Rats, Long-Evans | 1 | 2016 | 22 | 0.130 |
Why?
|
| Models, Cardiovascular | 1 | 2017 | 79 | 0.130 |
Why?
|
| Pseudophakia | 1 | 2016 | 3 | 0.130 |
Why?
|
| Animals | 6 | 2018 | 20627 | 0.130 |
Why?
|
| Educational Measurement | 1 | 2018 | 216 | 0.130 |
Why?
|
| Metaplasia | 1 | 2016 | 18 | 0.130 |
Why?
|
| Polytetrafluoroethylene | 1 | 2016 | 18 | 0.130 |
Why?
|
| Ocular Hypertension | 1 | 2016 | 9 | 0.130 |
Why?
|
| Age Distribution | 1 | 2017 | 258 | 0.130 |
Why?
|
| Retinoscopy | 1 | 2016 | 3 | 0.130 |
Why?
|
| Global Health | 1 | 2017 | 183 | 0.130 |
Why?
|
| Plasmapheresis | 1 | 2016 | 18 | 0.130 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 109 | 0.130 |
Why?
|
| Staphylococcus epidermidis | 1 | 2016 | 10 | 0.130 |
Why?
|
| Bortezomib | 1 | 2016 | 56 | 0.130 |
Why?
|
| Cyclophosphamide | 1 | 2016 | 79 | 0.130 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2016 | 32 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 4 | 2016 | 3391 | 0.120 |
Why?
|
| Watchful Waiting | 1 | 2016 | 28 | 0.120 |
Why?
|
| Polysomnography | 1 | 2016 | 57 | 0.120 |
Why?
|
| Needles | 1 | 2016 | 67 | 0.120 |
Why?
|
| Vision Disorders | 1 | 2016 | 64 | 0.120 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2017 | 178 | 0.120 |
Why?
|
| Prevalence | 1 | 2019 | 1365 | 0.120 |
Why?
|
| Cytoskeletal Proteins | 1 | 2016 | 200 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 371 | 0.120 |
Why?
|
| Penicillins | 1 | 2015 | 30 | 0.120 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 1644 | 0.120 |
Why?
|
| Drug Costs | 1 | 2015 | 56 | 0.120 |
Why?
|
| Drug Combinations | 1 | 2015 | 165 | 0.120 |
Why?
|
| Blood Transfusion | 1 | 2016 | 161 | 0.120 |
Why?
|
| Eye Enucleation | 1 | 2014 | 9 | 0.110 |
Why?
|
| Rats | 2 | 2016 | 1980 | 0.110 |
Why?
|
| Infusions, Intravenous | 1 | 2015 | 174 | 0.110 |
Why?
|
| Conjunctiva | 1 | 2014 | 4 | 0.110 |
Why?
|
| Observer Variation | 1 | 2015 | 211 | 0.110 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2014 | 19 | 0.110 |
Why?
|
| Acyclovir | 1 | 2014 | 20 | 0.110 |
Why?
|
| Valine | 1 | 2014 | 32 | 0.110 |
Why?
|
| Epithelium, Corneal | 1 | 2014 | 6 | 0.110 |
Why?
|
| Vitreoretinopathy, Proliferative | 1 | 2013 | 3 | 0.110 |
Why?
|
| Reference Values | 1 | 2014 | 337 | 0.110 |
Why?
|
| Antigens, Viral | 1 | 2014 | 135 | 0.110 |
Why?
|
| Viscosity | 1 | 2013 | 51 | 0.110 |
Why?
|
| ErbB Receptors | 1 | 2014 | 114 | 0.110 |
Why?
|
| Capsid Proteins | 1 | 2014 | 98 | 0.110 |
Why?
|
| DNA, Viral | 1 | 2014 | 232 | 0.100 |
Why?
|
| Risk Factors | 2 | 2014 | 5315 | 0.100 |
Why?
|
| Anterior Chamber | 1 | 2013 | 5 | 0.100 |
Why?
|
| Chronic Disease | 1 | 2016 | 751 | 0.100 |
Why?
|
| Databases, Factual | 1 | 2016 | 854 | 0.100 |
Why?
|
| HLA-B7 Antigen | 1 | 2012 | 2 | 0.100 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2012 | 17 | 0.100 |
Why?
|
| Electroretinography | 1 | 2012 | 26 | 0.100 |
Why?
|
| Ophthalmic Solutions | 1 | 2012 | 7 | 0.100 |
Why?
|
| Tetracaine | 1 | 2012 | 7 | 0.100 |
Why?
|
| Propoxycaine | 1 | 2012 | 5 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2018 | 692 | 0.100 |
Why?
|
| Visual Fields | 1 | 2012 | 49 | 0.100 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 467 | 0.100 |
Why?
|
| Antibodies, Viral | 1 | 2014 | 322 | 0.100 |
Why?
|
| Anesthesia | 1 | 2012 | 51 | 0.090 |
Why?
|
| Refractive Errors | 1 | 2011 | 12 | 0.090 |
Why?
|
| Anesthetics, Local | 1 | 2012 | 71 | 0.090 |
Why?
|
| Physiology | 1 | 2011 | 5 | 0.090 |
Why?
|
| Homeostasis | 1 | 2014 | 368 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2014 | 322 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2016 | 620 | 0.090 |
Why?
|
| Acute Disease | 1 | 2012 | 671 | 0.080 |
Why?
|
| Sensitivity and Specificity | 3 | 2018 | 1141 | 0.080 |
Why?
|
| History, 21st Century | 1 | 2011 | 170 | 0.080 |
Why?
|
| History, 20th Century | 1 | 2011 | 230 | 0.080 |
Why?
|
| Fundus Oculi | 1 | 2009 | 22 | 0.080 |
Why?
|
| Mice | 4 | 2016 | 10826 | 0.080 |
Why?
|
| Corneal Edema | 1 | 2009 | 1 | 0.080 |
Why?
|
| Syndrome | 1 | 2009 | 179 | 0.080 |
Why?
|
| Cicatrix | 1 | 2009 | 61 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 787 | 0.080 |
Why?
|
| Retreatment | 1 | 2008 | 47 | 0.080 |
Why?
|
| Injections | 1 | 2008 | 81 | 0.070 |
Why?
|
| Software | 1 | 2011 | 384 | 0.070 |
Why?
|
| Hemoglobins | 1 | 2008 | 135 | 0.070 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 2655 | 0.070 |
Why?
|
| Time Factors | 1 | 2012 | 3754 | 0.060 |
Why?
|
| Cell Line | 2 | 2016 | 2039 | 0.040 |
Why?
|
| Calibration | 1 | 2018 | 67 | 0.040 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2016 | 20 | 0.030 |
Why?
|
| Pattern Recognition, Automated | 1 | 2017 | 53 | 0.030 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2016 | 33 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 39 | 0.030 |
Why?
|
| Dextrans | 1 | 2016 | 46 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2016 | 186 | 0.030 |
Why?
|
| Machine Learning | 1 | 2017 | 175 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2016 | 495 | 0.030 |
Why?
|
| Tears | 1 | 2014 | 5 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 991 | 0.030 |
Why?
|
| Ligands | 1 | 2014 | 417 | 0.030 |
Why?
|
| Wound Healing | 1 | 2014 | 189 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2014 | 390 | 0.020 |
Why?
|
| Apoptosis | 1 | 2016 | 1071 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 2561 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2014 | 2157 | 0.020 |
Why?
|
| alpha-Globins | 1 | 2008 | 5 | 0.020 |
Why?
|
| Rats, Inbred BN | 1 | 2008 | 26 | 0.020 |
Why?
|
| beta-Globins | 1 | 2008 | 9 | 0.020 |
Why?
|
| Erythroblasts | 1 | 2008 | 15 | 0.020 |
Why?
|
| Peptide Mapping | 1 | 2008 | 29 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2008 | 39 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2008 | 84 | 0.020 |
Why?
|
| Cytosol | 1 | 2008 | 180 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 455 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 545 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2008 | 611 | 0.020 |
Why?
|
| Proteomics | 1 | 2008 | 284 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 892 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2008 | 1534 | 0.010 |
Why?
|